Factor Xa inhibitors: all 607 studies that test it

Page 2 of 7. Open to participants first (111), then studies with results posted, then the rest; newest registration first within each.

• COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial FibrillationRecruitingNCT04642430Phase 4
• AnticoaguLation ONE Year After Ablation of Atrial Fibrillation in Patients With Atrial Fibrillation (ALONE AF Study)RecruitingNCT04432220Phase 4
• The Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery TrialRecruitingNCT04284839Phase 3
• Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary EmbolismRecruitingNCT04263038Phase 4
• Long-term Anticoagulation With Oral Factor Xa Inhibitor Versus Vitamin K Antagonist After Mechanical Aortic Valve ReplacementRecruitingNCT04258488Phase 4
• Rivaroxaban for the Prevention of Deep Vein Thrombosis in Patients With Left Iliac Vein Compression - The PLICTS StudyRecruitingNCT04067505Phase 3
• Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava FiltersRecruitingNCT04066764Phase 3
• MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke PreventionRecruitingNCT03961334Phase 3
• Anticoagulation in ICH Survivors for Stroke Prevention and RecoveryRecruitingNCT03907046Phase 3
• Left Atrial Appendage Occlusion Versus Novel Oral Anticoagulation for Stroke Prevention in Atrial FibrillationRecruitingNCT03642509Not applicable
• Avoiding Anticoagulation After IntraCerebral HaemorrhageRecruitingNCT03243175Phase 3
• Xarelto for Thromboprophylaxis After Total Hip and Total Knee ArthroplastyCompletedNCT05449327Not applicableResults posted
• WILL lOWer Dose Aspirin be Better With Rivaroxaban in Patients With Chronic Coronary Syndromes?CompletedNCT04990791Phase 4Results posted
• DOT HeartMate 3 StudyCompletedNCT04974684Not applicableResults posted
• An Exploratory stuDy of effectIveneSs and Safety of rivarOxaban in Patients With Left VEntricular Thrombus (R-DISSOLVE)CompletedNCT04970381Not applicableResults posted
• Evaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist DevicesCompletedNCT04865978Phase 2Results posted
• COVID-19 Thrombosis Prevention Trials: Post-hospital ThromboprophylaxisCompletedNCT04650087Phase 3Results posted
• A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) InfectionTerminatedNCT04508023Phase 3Results posted
• Apixaban vs Enoxaparin Following Microsurgical Breast Reconstruction-An RCTCompletedNCT04504318Phase 1/2Results posted
• A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19)TerminatedNCT04504032Phase 2Results posted
• COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80TerminatedNCT04498273Phase 3Results posted
• Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous ThromboembolismCompletedNCT04168203Phase 4Results posted
• PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on ApixabanTerminatedNCT04142658Phase 3Results posted
• Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery DiseaseCompletedNCT04006288Phase 4Results posted
• Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health VolunteersCompletedNCT03864406Phase 1Results posted
• Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial FibrillationTerminatedNCT03839355Phase 3Results posted
• Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet TherapiesCompletedNCT03718429Phase 4Results posted
• Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial FibrillationCompletedNCT03702582Phase 3Results posted
• Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT)TerminatedNCT03594045Phase 2Results posted
• Calf Deep Vein Thrombosis Treatment TrialTerminatedNCT03590743Phase 4Results posted
• Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 4 of 4)CompletedNCT03551743Phase 2Results posted
• Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous LinesCompletedNCT03506815Phase 3Results posted
• Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac DiseaseCompletedNCT03395639Phase 3Results posted
• Study Evaluating Betrixaban in Pediatric ParticipantsTerminatedNCT03346083Phase 1Results posted
• Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous ThromboembolismCompletedNCT03266783Phase 4Results posted
• A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement SurgeryCompletedNCT03251482Phase 2Results posted
• Comparison of Oral Anticoagulants for Extended VEnous ThromboembolismTerminatedNCT03196349Phase 4Results posted
• AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic StrokeTerminatedNCT03192215Phase 3Results posted
• Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation TherapyCompletedNCT03080883Phase 3Results posted
• Apixaban for the Treatment of Venous Thromboembolism in Patients With CancerCompletedNCT03045406Phase 3Results posted
• Apixaban Versus Warfarin in Patients With Left Ventricular ThrombusCompletedNCT02982590Phase 3Results posted
• A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring AnticoagulationCompletedNCT02981472Phase 2Results posted
• Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple MyelomaCompletedNCT02958969Phase 4Results posted
• Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)CompletedNCT02943785Phase 3Results posted
• Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter AblationCompletedNCT02942576Phase 3Results posted
• Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial FibrillationCompletedNCT02942407Phase 4Results posted
• Apixaban Versus Warfarin for the Management of Post-operative Atrial FibrillationCompletedNCT02889562Phase 2/3Results posted
• Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary InterventionCompletedNCT02866175Phase 3Results posted
• Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan ProcedureCompletedNCT02846532Phase 3Results posted
• Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)CompletedNCT02833948Phase 3Results posted
• RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual BleedingCompletedNCT02829957Phase 2/3Results posted
• Study of DU-176b Aged 80 Years or OlderCompletedNCT02801669Phase 3Results posted
• Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)CompletedNCT02798471Phase 3Results posted
• A Pilot Study Investigating Apixaban and Dexamethasone InterAction in Multiple MyelomaTerminatedNCT02749617Phase 2Results posted
• Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in CancerCompletedNCT02744092Not applicableResults posted
• DOACs for Stroke Prevention Post Ventricular Tachycardia AblationCompletedNCT02666742Phase 4Results posted
• Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate EpisodesTerminatedNCT02618577Phase 3Results posted
• Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous ThromboembolismCompletedNCT02585713Phase 3Results posted
• A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency DepartmentCompletedNCT02584660Phase 4Results posted
• Rivaroxaban for Treatment in Venous or Arterial Thrombosis in NeonatesCompletedNCT02564718Phase 1/2Results posted
• EdoxabaN or Warfarin Therapy In Device Procedures in Patients With Non-Valvular Atrial FibrillationTerminatedNCT02561897Phase 4Results posted
• Comparison of Bleeding Risk Between Rivaroxaban and Apixaban: The Pilot StudyCompletedNCT02559856Phase 4Results posted
• Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical OutcomesTerminatedNCT02556203Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer ParticipantsCompletedNCT02555878Phase 3Results posted
• XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed ThrombolysisTerminatedNCT02506985Phase 4Results posted
• Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower ExtremitiesCompletedNCT02504216Phase 3Results posted
• Apixaban for the Acute Treatment of Venous Thromboembolism in ChildrenCompletedNCT02464969Phase 4Results posted
• A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the HeartCompletedNCT02415400Phase 4Results posted
• Apixaban Pharmacokinetics in Bariatric Patients (APB)CompletedNCT02406885Phase 4Results posted
• Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary CalciumCompletedNCT02376010Phase 4Results posted
• A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With AsparaginaseCompletedNCT02369653Phase 3Results posted
• Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic MalignancyCompletedNCT02366871Phase 2Results posted
• Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and StomachTerminatedNCT02358863Not applicableResults posted
• Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV DiseaseCompletedNCT02339415Phase 2Results posted
• Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)TerminatedNCT02313909Phase 3Results posted
• EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous ThrombosisCompletedNCT02309411Phase 2Results posted
• A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary SyndromeCompletedNCT02293395Phase 2Results posted
• Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic TransformationCompletedNCT02283294Phase 3Results posted
• Pilot Study to Examine the Use of Rivaroxaban After Angioplasty for Critical Limb IschemiaCompletedNCT02260622Phase 2Results posted
• EINSTEIN Junior: Oral Rivaroxaban in Children With Venous ThrombosisCompletedNCT02234843Phase 3Results posted
• Apixaban in Patients With Sickle Cell DiseaseTerminatedNCT02179177Phase 3Results posted
• Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Aspirin in Type-2 Diabetic Patients With Subclinical Inflammation and High Cardiovascular RiskCompletedNCT02164578Phase 3Results posted
• A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge PatientsCompletedNCT02111564Phase 3Results posted
• Bioavailability of Apixaban Crushed TabletCompletedNCT02101112Phase 1Results posted
• Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)CompletedNCT02100228Phase 4Results posted
• Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable PlaqueCompletedNCT02090075Phase 4Results posted
• Cancer Venous Thromboembolism (VTE)CompletedNCT02073682Phase 3Results posted
• The Effect of Rivaroxaban in Sickle Cell DiseaseCompletedNCT02072668Phase 2Results posted
• Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)CompletedNCT02072434Phase 3Results posted
• Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)CompletedNCT02064439Phase 3Results posted
• Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial FibrillationCompletedNCT02042534Phase 2Results posted
• Phase 1 Oral Solution and Crushed Tablet Relative Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy SubjectsCompletedNCT02034591Phase 1Results posted
• Phase 1 Oral Solution Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy SubjectsCompletedNCT02034578Phase 1Results posted
• Phase 1 Bioavailability Study of Apixaban Solution Formulation Relative to Apixaban Tablets in Healthy SubjectsCompletedNCT02034565Phase 1Results posted
• Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)CompletedNCT01884350Phase 4Results posted
• Multi-center Study to Evaluate the Safety of Apixaban (BMS-562247) in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement SurgeryCompletedNCT01884337Phase 4Results posted
• A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart FailureCompletedNCT01877915Phase 3Results posted
• Safety and Pharmacokinetics Study of DU-176b Administered to Non-valvular Atrial Fibrillation With Severe Renal ImpairmentCompletedNCT01857622Phase 3Results posted
• Safety and Pharmacokinetics Study of DU-176b Administered to Patients With Severe Renal Impairment Undergoing Orthopedic Surgery of The Lower LimbsCompletedNCT01857583Phase 3Results posted
• A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary InterventionCompletedNCT01830543Phase 3Results posted

← Factor Xa inhibitors overview